Carvykti Surpasses $1.3 Billion in Sales, Joins Blockbuster Drug Ranks

Recently, Johnson & Johnson released its third-quarter financial report for 2025. The data shows that the CAR-T cell therapy drug Ciltacabtagene Autoleucel Injection (Chinese trade name: Carvykti, English trade name: Carvykti), co-developed with Legend Biotech, achieved sales of $524 million in this quarter, representing a year-on-year increase of 83% and a quarter-on-quarter increase of 19.4%, setting a new high for single-quarter sales since its market launch.

So far, Carvykti's cumulative sales in the first three quarters of this year have reached $1.332 billion, successfully entering the "blockbuster" category., referring to annual sales exceeding 1 billion US dollars) drug category, representing a significant increase of 112% compared to $629 million in the same period last year, achieving a doubling in growth. If the strong growth momentum is maintained in the fourth quarter, Carvykti is expected to surpass the $2 billion sales mark for the full year of 2025. Since its launch, Carvykti's global sales have continued to rise, with global revenue reaching $963 million in 2024, demonstrating robust growth momentum.

Carvykti is a CAR-T cell therapy drug with two single-domain antibodies targeting B-cell maturation antigen (BCMA). It has been approved for marketing in multiple countries and regions, including China, the United States, the European Union, and Japan, for the treatment of relapsed or refractory multiple myeloma (R/R MM). Data shows,CarvyktiIn patients with relapsed or refractory multiple myeloma who have previously received four or more lines of therapy (including proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies), it demonstrated an overall response rate of up to 98%. Last year, the United States and the European Union successively approved its use for second-line treatment, significantly advancing the clinical application pathway.

In June 2025, Legend Biotech announced the latest long-term follow-up data for Carvykti in patients with relapsed or refractory multiple myeloma. The results showed that 33% (32/97) of patients who received a single infusion and did not undergo maintenance therapy or subsequent treatment had no disease progression for five years or longer.Disease progression,Set the longest record of remission in this field.

Currently, there are only two CAR-T cell therapies approved for multiple myeloma in the U.S. market — Legend Biotech's Carvykti and Bristol-Myers Squibb's (BMS) Abecma. Although both significantly outperform traditional chemotherapy, Carvykti demonstrates superior efficacy and safety, capturing approximately 90% of the BCMA-targeted CAR-T market and establishing an absolute leading position.

Notably, Carvykti exhibits a unique delayed onset characteristic of cytokine release syndrome (CRS), allowing nearly half of the patients to complete treatment on an outpatient basis without prolonged hospitalization. This advantage not only alleviates the bed pressure in medical institutions but also significantly reduces overall healthcare costs, making it highly favored by health insurance payers.

To meet the growing global clinical demand, Legend Biotech previously revealed plans to double Carvykti's annual production capacity to 10,000 batches by the end of 2025, and further expand to 20,000 batches by 2027.

E.N.D

ForPromote Cooperation and Technical Exchange in the Cell and Gene Therapy IndustryThe team of the WeChat Official Account "Cell and Gene Therapy Field" has established a professional communication group for cell and gene therapy. Press and hold the QR code below to add the editor's WeChat and join the group. Due to the large number of applicants, please include the following information when adding WeChat: Institution/Enterprise—Major/Position—Name. If you are a PI/Professor/Manager or above, please also indicate.